What Prompted Vivo Capital's Exit from Cidara Therapeutics

What Prompted Vivo Capital’s Exit from Cidara Therapeutics

May 15, 2026

Key Takeaways

Merck’s $9.2 billion acquisition of Cidara Therapeutics for $221.50 per share was a strategic move to bolster its pipeline with the late-stage antiviral CD388 ahead of the Keytruda patent cliff.
Vivo Capital’s complete divestment of its Cidara position was a natural and successful outcome of the acquisition, converting its equity stake into cash at the tender offer price.
While Cidara stock is now delisted, the deal highlights the increasing appetite for M&A in the biotech sector, driven by big pharma’s need for innovative, de-risked assets.

What Prompted Vivo Capital’s Exit from Cidara Therapeutics?

Vivo Capital’s complete divestment of its $211 million position in Cidara Therapeutics was not a signal of distress but rather the successful culmination of a strategic investment. The healthcare-focused investment firm exited its entire stake because Cidara Therapeutics was acquired by pharmaceutical giant Merck & Co. for approximately $9.2 billion. This transaction, announced on November 17, 2025, and completed on January 7, 2026, saw Merck acquire all outstanding shares of Cidara common stock for $221.50 per share in cash.

For a venture capital or growth equity firm like Vivo Capital, an acquisition by a larger entity represents a primary exit strategy and a significant return on investment. Once the tender offer was completed and the merger finalized, Cidara became a wholly-owned subsidiary of Merck, and its common stock was delisted from the Nasdaq Global Market. Consequently, Vivo Capital’s previously held shares were converted into the cash offer price, leading to their reported 0% ownership stake in Cidara as of January 7, 2026. This is a textbook example of a successful portfolio company exit for an institutional investor in the biotech space.

The acquisition price itself represented a substantial premium for Cidara shareholders. Prior to the deal announcement, Cidara shares had climbed 600% over the preceding year, reaching over $105 apiece, reflecting growing optimism around its lead candidate. Merck’s offer of $221.50 per share translated to a 109% premium over Cidara’s closing price on November 13, 2025, the day before the news was first reported. This robust valuation underscores the perceived value of Cidara’s pipeline, particularly its lead asset, CD388, which became the cornerstone of Merck’s strategic rationale.

Why Did Merck Pay $9.2 Billion for Cidara?

Merck’s $9.2 billion acquisition of Cidara Therapeutics was a calculated, strategic maneuver to fortify its pipeline with a potentially transformative asset, CD388, a long-acting antiviral agent for influenza prevention. This substantial investment aligns with Merck’s broader business development strategy of acquiring compelling science to offset future revenue challenges. The pharmaceutical giant faces the looming patent expiration of its blockbuster cancer immunotherapy, Keytruda, later this decade, necessitating the rapid integration of new, high-potential revenue streams.

CD388, Cidara’s lead candidate, is an investigational, long-acting, and strain-agnostic antiviral designed to prevent both influenza A and B infections. Unlike traditional vaccines, it combines a small molecule neuraminidase inhibitor with an Fc fragment from a human antibody, creating a therapeutic intended to provide universal protection against seasonal and pandemic influenza with a single dose. This unique mechanism of action and the potential for once-a-season subcutaneous administration make CD388 a highly attractive asset, particularly for high-risk individuals who may not respond adequately to vaccines or require additional protection.

Merck CEO Robert M. Davis emphasized that the acquisition “strengthens and complements our expanding respiratory portfolio and exemplifies our business development strategy of investing where compelling science and value meet.” The deal is the latest in a series of significant acquisitions for Merck, including the $10 billion buyout of Verona Pharma in July 2025 and the $11.5 billion Acceleron deal. These moves collectively demonstrate Merck’s aggressive pursuit of late-stage assets to drive growth and diversify its revenue base in the post-Keytruda era. The market opportunity for CD388 is significant, with RBC Capital Markets analysts projecting a $3.8 billion peak sales potential for the drug.

What is CD388 and Its Market Potential?

CD388 is the crown jewel of Cidara Therapeutics’ pipeline and the primary driver behind Merck’s $9.2 billion acquisition. This investigational drug-Fc conjugate (DFC) is designed as a long-acting, strain-agnostic antiviral for the prevention of symptomatic influenza in high-risk individuals. Its innovative mechanism combines zanamivir, the active ingredient in GSK’s Relenza, with an engineered human antibody fragment. This conjugation extends its durability, allowing for a single-dose, universal preventative agent that could offer protection against all flu virus strains for an entire season.

Clinical data has been promising. In a mid-stage challenge study (Phase 2b NAVIGATE) involving healthy, unvaccinated adults aged 18 to 64, a single dose of CD388 demonstrated up to 76% protection against symptomatic influenza over a 24-week period compared with placebo. Specifically, a 150-mg dose showed 57.7% prevention efficacy, which improved to 61.3% at the 300-mg level and 76.1% at 450 mg against influenza A and B. These results, coupled with “no apparent safety issues,” underscore the drug’s potential to become a significant player in influenza prevention.

The drug is currently advancing through Phase III clinical trials (ANCHOR trial), targeting enrollment of 6,000 patients, including healthy seniors, adults, and teens at higher risk of influenza complications. CD388 has also been granted Fast Track and Breakthrough Therapy designations by the FDA, which could expedite its review process. The market opportunity is substantial, particularly for vulnerable populations where vaccine efficacy may be insufficient. If Phase 3 results mirror the Phase 2b success, CD388 could become a multi-billion-dollar annual revenue source for Merck, offering a stable, predictable income stream driven by ongoing seasonal needs, a critical factor as Keytruda’s patent protection expires.

What Are the Financial Implications for Cidara and Merck?

For Cidara Therapeutics, the financial implications of the Merck acquisition are straightforward and conclusive: the company has ceased to exist as an independent, publicly traded entity. As of January 7, 2026, Cidara became a wholly-owned subsidiary of Merck, and its common stock was delisted from the Nasdaq Global Market. Shareholders who tendered their shares received $221.50 per common share in cash. Those who did not tender their shares had them cancelled and converted into the right to receive the same $221.50 offer price, without interest and subject to tax withholding. This effectively cashed out all Cidara investors, including institutional holders like Vivo Capital.

From Merck’s perspective, the acquisition carries significant financial implications, particularly in the short to medium term. The deal is expected to be accounted for as an asset acquisition, which will result in a substantial charge. Merck anticipates this charge will increase its 2026 research and development expenses by approximately $9.0 billion, or about $3.65 per share, impacting both GAAP and non-GAAP results. Additionally, GAAP and non-GAAP EPS are expected to be negatively impacted by approximately $0.30 per share in the first 12 months post-acquisition. These are considerable upfront costs, reflecting the high premium paid for a late-stage asset with significant future revenue potential.

Analyst sentiment shifted immediately following the acquisition announcement. Firms like JPMorgan and Needham downgraded Cidara’s rating from “Buy” to “Neutral” or “Hold,” and adjusted their price targets to align with the $221.50 offer price. This is a standard practice when a company is acquired, as the upside for investors becomes capped at the acquisition price, removing the rationale for a “Buy” rating. Cidara’s TTM financial fundamentals prior to the acquisition reflected a development-stage biotech, with $0.00 revenue, an EPS of -$11.88, and negative margins and returns, underscoring the speculative nature of its stock before the CD388 data and Merck’s interest materialized.

What Does This Mean for the Broader Biotech M&A Landscape?

The Merck-Cidara deal serves as a powerful indicator of the current dynamics and future trajectory of the biotech mergers and acquisitions (M&A) landscape. This $9.2 billion transaction, one of the largest in the sector in 2025, highlights big pharma’s aggressive strategy to acquire innovative, late-stage assets to replenish pipelines and secure future growth. With major pharmaceutical companies facing significant patent cliffs for their top-selling drugs, the urgency to bring new therapies to market has intensified, fueling a robust M&A environment.

The acquisition underscores a clear preference for de-risked assets, particularly those in Phase 3 clinical trials or with Fast Track/Breakthrough designations, like Cidara’s CD388. These assets offer a higher probability of regulatory approval and a clearer path to market, reducing the inherent risks associated with early-stage drug development. This trend suggests that smaller biotech firms with promising, advanced-stage candidates will continue to be attractive targets, commanding significant premiums. The 109% premium Merck paid for Cidara is a testament to the perceived value of such assets in a competitive market.

Moreover, this deal reinforces the notion that big pharma is actively diversifying its therapeutic portfolios. Merck’s focus on respiratory diseases and infectious disease prevention with CD388 demonstrates a strategic shift beyond traditional therapeutic areas, seeking broad-market opportunities. The deal also signals a broader upturn in biotech dealmaking, with October 2025 being the most active month for company acquisitions in years. This resurgence in M&A activity is likely to continue as large pharmaceutical companies leverage their strong balance sheets to acquire innovation, ensuring sustained growth and mitigating the impact of patent expirations.

The Merck-Cidara acquisition, culminating in Vivo Capital’s successful exit, exemplifies the strategic imperative driving biotech M&A. It underscores big pharma’s willingness to pay substantial premiums for late-stage, de-risked assets like CD388 to secure future revenue streams. For investors, this trend highlights the potential for significant returns in smaller biotech companies with innovative pipelines, particularly as the broader M&A landscape remains robust.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.